The National Cancer Institute (NCI) is soliciting Phase I Small Business Innovation Research (SBIR) proposals under an Innovative Concept Award program for high-risk, high-reward R&D in pediatric and/or rare cancers, with rare cancers defined as those with a 5-year survival rate below 50%. Two topic areas are sought: therapeutic or preventative technologies, and devices, diagnostic technologies, or digital health tools for these cancers. Proposals do not require preliminary data but must demonstrate sound scientific premise, identify the clinical problem and cancer types, and propose experiments for proof-of-concept and de-risking; non-exempt human subjects research will not be supported. Amendment #2 removed the Data Management Sharing Plan requirement and related evaluation references, while Amendment #3 provides written Q&A and requires a signed SF30 amendment page with the Business Proposal submission. All other terms and conditions remain unchanged, and awards are subject to availability of funds.

The National Cancer Institute (NCI) is seeking small business proposals for Phase I SBIR contracts focused on high-risk, high-reward research. The solicitation targets two topic areas: therapeutic or preventative technologies for pediatric and rare cancers, and devices, diagnostics, or digital health tools for the same cancers, with a preference for rare cancers having a 5-year survival rate under 50%. Proposals must demonstrate proof-of-concept and feasibility for transformative technologies, with sound scientific premise but no preliminary data required. Non-exempt human subjects research will not be supported, and performance location is not specified. No budget amounts or submission timelines are provided in the description.

The National Cancer Institute (NCI) is seeking small business proposals for a high-risk, high-reward Phase I SBIR contract focused on developing transformative technologies for pediatric and rare cancers. Proposals must target a specific clinical problem and cancer type, with an emphasis on rare cancers having a 5-year survival rate below 50%, and should demonstrate sound scientific premise without requiring preliminary data. The solicitation covers two topics: therapeutic or preventative technologies, and devices, diagnostic technologies, or digital health tools. Non-exempt human subjects research will not be supported, and only one Phase II award may result from a Phase I contract. No budget amounts or performance location are specified.

The National Cancer Institute (NCI) is seeking small business proposals for Phase I SBIR contracts focused on high-risk, high-reward research and development for pediatric and rare cancers with a 5-year survival rate under 50%. The solicitation covers two topic areas: therapeutic or preventative technologies, and devices, diagnostic technologies, or digital health tools. Proposals must demonstrate sound scientific premise, identify a clinical problem and cancer type, and propose experiments for proof-of-concept and de-risking, though preliminary data is not required. Non-exempt human subjects research will not be supported, and no budget amounts or performance location are specified. Phase I awardees may later apply for Phase II, but only one Phase II award may result from a single Phase I contract.

The National Cancer Institute (NCI) is seeking small business proposals for Phase I SBIR contracts focused on high-risk, high-reward research and development for pediatric and rare cancers with a 5-year survival rate below 50%. The solicitation covers two topic areas: therapeutic or preventative technologies, and devices, diagnostic technologies, or digital health tools. Proposals must demonstrate sound scientific premise, identify a clinical problem and cancer type, and propose experiments for proof-of-concept, though preliminary data is not required. Non-exempt human subjects research will not be supported, and Phase I awardees may later apply for a single Phase II award. No specific timelines, budget amounts, or performance location are mentioned in the description.